H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ :: Cabaletta Bio, Inc. (CABA)

Contact

Our RESET^TM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, and myasthenia gravis are now recruiting.

H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Webcast